The safety and efficacy of a locally available probiotic in premature infants.
A randomised placebo controlled pilot trial on the safety and efficacy of a probiotic product in reducing all case mortality and definite necrotizing enterocolitis in preterm very low birthweight neonates.
Womens and Childrens Health Service
120 participants
Dec 7, 2010
Interventional
Conditions
Summary
This is a two stage project: (1) independent microbiological studies to confirm the identity of the probiotic bacteria and the safety (contaminants, unspecified contents, osmolarity) of the probiotic product followed by (2) a pilot clinical trial to test the hypothesis that routine supplementation with this probiotic product will result in colonisation of the gut (primary hypothesis) and reduction in all cause deaths, and diseases like NEC, and late onset sepsis (secondary hypotheses) in premature babies.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
This is a prospective double blind placebo controlled randomised trial investigating the safety and efficacy of a locally available probiotic product. Enrolled neonates will be allocated to the product (containing Lactobacillus acidophilus 375 million, Bifidobacterium bifidum & Bifidobacterium longus 125 million organisms) or an identical looking placebo containing maltodextrin. This is available in tablet form, which is crushed and mixed with 3ml of sterile water at the bedside, and given twice daily by mouth / gastric tube, from the start of enteral feeds until discharged home or term (37 weeks post menstral age) whichever comes first.
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12609000374268